Related Experiment Videos
Detecting mitomycin C in human plasma during intravesical therapy
Abstract:
Mitomycin C (MMC) concentrations in plasma and urine were measured in five patients with intact bladder during intravesical instillation therapy. No MMC was detected in plasma by a selective high performance liquid chromatographic (HPLC) method. The detection limit of the method is 1 ng/ml. Our results are in accordance with clinical experiences of the lack of systemic toxicity during MMC instillation therapy. There was a remarkable loss of MMC in the voided urine. The probable explanation could be that a considerable amount of MMC is absorbed into the bladder wall.
Insights
This study found no systemic absorption of Mitomycin C (MMC) in patients receiving intravesical instillation therapy, indicating low systemic toxicity. Significant MMC loss in urine suggests bladder wall absorption.
Area of Science:
- Urology
- Pharmacology
- Oncology
Background:
- Intravesical Mitomycin C (MMC) is used for bladder cancer treatment.
- Systemic toxicity is a concern with intravesical therapies.
- Understanding MMC pharmacokinetics is crucial for safety and efficacy.
Purpose of the Study:
- To quantify Mitomycin C (MMC) concentrations in plasma and urine.
- To assess systemic absorption and potential toxicity during intravesical instillation.
- To investigate MMC disposition in patients with intact bladders.
Main Methods:
- Selective high-performance liquid chromatography (HPLC) was employed for precise MMC quantification.
- Plasma and urine samples were collected from five patients undergoing intravesical MMC therapy.
- A sensitive detection limit of 1 ng/ml was established for MMC analysis.
Main Results:
- No Mitomycin C (MMC) was detected in patient plasma samples.
- The HPLC method demonstrated a detection limit of 1 ng/ml.
- A significant reduction in MMC concentration was observed in voided urine.
Conclusions:
- Intravesical Mitomycin C (MMC) instillation therapy shows minimal systemic absorption in patients with intact bladders.
- The observed lack of plasma MMC supports the clinical experience of low systemic toxicity.
- Substantial urinary MMC loss suggests significant absorption into the bladder wall, warranting further investigation.